EUnetHTA Magazine: Winter 2019
Assessment Publication: Jointly Produced HTA Report; Partner Profile: Austria; Impact: Austria; Partner Profile: UK; Innovation & HTA: Giovanni Tafuri; Prioritisation List: Topics & Joint Assessments; 2018: Year in Review Download your copy HERE.
PTJA04 – “Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy” is now available
This is the assessment of the relative effectiveness of ‘Sotagliflozin is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.’ Below is the documentation provided […]
EUnetHTA 2019 Forum
Registration has now closed for the EUnetHTA 2019 Forum, held this year at the West-Indisch Huis in Amsterdam, the Netherlands, on 11 April 2019. Consisting of EUnetHTA Consortium partners, stakeholder groups, and other organisations involved in the activities of EUnetHTA JA3, the Forum provides a focal point for the open exchange of ideas and experience […]
The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” is now available.
The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” is now available. We are pleased to announce that the collaborative rapid assessment on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute […]
OTCA16 Bioresorbable Stents for the Treatment of Cardiovascular Indications (coronary artery disease) Final Assessment Now Available.
We are pleased to announce that the collaborative rapid assessment, OTCA16, on “BIORESORBABLE STENTS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS (CORONARY ARTERY DISEASE)” is now available. The health technology assessed is a device for percutaneous coronary intervention (PCI). The objective of this assessment was to evaluate the relative effectiveness and safety of this technology in […]
OCTA20 “Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)” final project plan now available.
The final project plan of the assessment OTCA20 on “Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)” and the comments provided by external experts and the manufacturer are now available. OTCA20 Final Project Plan HERE OTCA20 External Expert & Manufacturer Comments HERE
The Collaborative Assessment, OTCA06, on “Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk” is now available
We are pleased to announce that the collaborative rapid assessment, OTCA06, on “TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) FOR THE TREATMENT OF PATIENTS AT INTERMEDIATE SURGICAL RISK” is available. The health technology assessed is a bioprothesis in the aortic valve deployed using a catheter. The objective of this assessment was to evaluate the relative effectiveness and […]
OTCA19 “Screening for osteoporosis in the general population” project plan now available
The final project plan of the assessment OTCA19 on “Screening for osteoporosis in the general population” and the comments provided by external experts are now available. OTCA19 Project Plan HERE OTCA19 External Expert Comments HERE
Implementation Report Now Available: National Uptake and Case Studies
Implementation Report – November 2018 Appendix: Case study on joint REA to inform economic evaluation – interview summaries Find all implementation reports HERE Find statistical graphics and usage maps HERE
Public consultation on medicinal product for relapsed or refractory Acute Myeloid Leukaemia (AML)
